本帖最后由 wsjboy 于 2013-3-26 23:49 编辑
BOT ALXA
ALXA Alexza Pharmaceuticals, Inc.
ALXA heal Alexza Pharmaceuticals Inc., drug manfctrrs-othr
alpha -47.09 beta 1.72 a_vol 294, insider -54.83,
===============
Alexza Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The company’s lead product candidate includes ADASUVE (Staccato loxapine) for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Its other product candidates under development comprise AZ-007 (Staccato zaleplon), which has completed Phase I clinical trials for the treatment of insomnia; and Staccato nicotine that is in pre-Phase 1 clinical trials to help smokers quit by addressing both the chemical and behavioral components of nicotine addiction by delivering nicotine replacement through inhalation. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Mountain View, California.
===============
Alexza公司制药公司，制药公司，从事新型专利产品的研究，开发和商业化的急性治疗中枢神经系统疾病全球。及其候选产品是基于一种专有技术，Staccato的系统，该蒸发无赋形剂的药物形成的缩合气溶胶，吸入时，允许快速的全身药物递送。公司的主导产品为成年人与精神分裂症或躁郁症的治疗急性激越的的候选人包括ADASUVE（Staccato的洛沙平）。它的其他产品正在开发中的候选人包括AZ-007（思加图扎来普隆），已完成第一阶段的临床试验，用于治疗失眠的和Staccato的尼古丁是前阶段的临床试验，以帮助吸烟者戒烟的同时处理的化学和提供尼古丁替代疗法通过吸入尼古丁的成瘾行为的组成部分。公司的前身为Alexza公司分子配送公司，并于2005年7月更名为Alexza公司制药公司。 Alexza公司制药公司成立于2000年，总部设在加利福尼亚州的山景城，。 |
发表于 2012-12-24 14:02
| 
